Canine Mothers Against Decapentaplegic Homolog 7 ELISA Kit | Smad7 elisa kit

Canine Mothers Against Decapentaplegic Homolog 7 ELISA Kit

Cat. Num. AAA743721

• Gene Names: SMAD7; CRCS3; MADH7; MADH8
• Reactivity: Canine
• Synonyms: Mothers Against Decapentaplegic Homolog 7; Canine Mothers Against Decapentaplegic Homolog 7 ELISA Kit; Smad7 elisa kit

• Reactivity: Canine

• Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate
• Assay Type: Sandwich
• Detection Range: 0.5-10ng/mL
• Sensitivity: 0.1ng/mL
• Intended Uses: This Smad7 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Canine Smad7. This ELISA kit for research use only, not for therapeutic applications!
• Preparation and Storage: Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Related Product Information for Smad7 elisa kit

Principle of the Assay: Smad7 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-Smad7 antibody and an Smad7-HRP conjugate. The assay sample and buffer are incubated together with Smad7-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the Smad7 concentration since Smad7 from samples and Smad7-HRP conjugate compete for the anti-Smad7 antibody binding site. Since the number of sites is limited, as more sites are occupied by Smad7 from the sample, fewer sites are left to bind Smad7-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The Smad7 concentration in each sample is interpolated from this standard curve.

Product Categories/Family for Smad7 elisa kit

Signal Transduction

NCBI and Uniprot Product Information

• NCBI GI #: 18418630
• NCBI GeneID: 4092
• Molecular Weight: 46,355 Da
• NCBI Official Full Name: Smad7
• NCBI Official Synonym Full Names: SMAD family member 7
• NCBI Official Symbol: SMAD7
• NCBI Official Synonym Symbols: CRCS3; MADH7; MADH8
• NCBI Protein Information: mothers against decapentaplegic homolog 7; hSMAD7; MAD homolog 8; mothers against DPP homolog 8; SMAD, mothers against DPP homolog 7; Mothers against decapentaplegic, drosophila, homolog of, 7; MAD (mothers against decapentaplegic, Drosophila) homolog 7
• UniProt Protein Name: Mothers against decapentaplegic homolog 7
• Protein Family: Mothers against decapentaplegic
• UniProt Gene Name: SMAD7
• UniProt Synonym Gene Names: MADH7; MADH8; MAD homolog 7; Mothers against DPP homolog 7; MAD homolog 8; Mothers against DPP homolog 8; SMAD 7; Smad7; hSMAD7
• UniProt Entry Name: SMAD7_HUMAN

NCBI Description

The protein encoded by this gene is a nuclear protein that binds the E3 ubiquitin ligase SMURF2. Upon binding, this complex translocates to the cytoplasm, where it interacts with TGF-beta receptor type-1 (TGFBR1), leading to the degradation of both the encoded protein and TGFBR1. Expression of this gene is induced by TGFBR1. Variations in this gene are a cause of susceptibility to colorectal cancer type 3 (CRCS3). Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2010]

Uniprot Description

SMAD7: Antagonist of signaling by TGF-beta (transforming growth factor) type 1 receptor superfamily members; has been shown to inhibit TGF-beta (Transforming growth factor) and activin signaling by associating with their receptors thus preventing SMAD2 access. Functions as an adapter to recruit SMURF2 to the TGF-beta receptor complex. Also acts by recruiting the PPP1R15A- PP1 complex to TGFBR1, which promotes its dephosphorylation. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. Genetic variations in SMAD7 influence susceptibility to colorectal cancer type 3 (CRCS3). Colorectal cancer consists of tumors or cancer of either the colon or rectum or both. Cancers of the large intestine are the second most common form of cancer found in males and females. Symptoms include rectal bleeding, occult blood in stools, bowel obstruction and weight loss. Treatment is based largely on the extent of cancer penetration into the intestinal wall. Surgical cures are possible if the malignancy is confined to the intestine. Risk can be reduced when following a diet which is low in fat and high in fiber. Belongs to the dwarfin/SMAD family.

Protein type: Transcription factor; DNA-binding

Chromosomal Location of Human Ortholog: 18q21.1

Cellular Component: nucleoplasm; transcription factor complex; protein complex; cell-cell adherens junction; cytoplasm; plasma membrane; catenin complex; nucleus; cytosol

Molecular Function: collagen binding; protein binding; metal ion binding; ubiquitin protein ligase binding; beta-catenin binding; activin binding; transforming growth factor beta receptor, inhibitory cytoplasmic mediator activity; transcription factor activity

Biological Process: transcription initiation from RNA polymerase II promoter; transcription, DNA-dependent; protein stabilization; negative regulation of transcription factor activity; negative regulation of peptidyl-serine phosphorylation; negative regulation of transcription from RNA polymerase II promoter; regulation of activin receptor signaling pathway; negative regulation of BMP signaling pathway; BMP signaling pathway; regulation of transforming growth factor beta receptor signaling pathway; positive regulation of protein ubiquitination; ureteric bud development; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; transforming growth factor beta receptor signaling pathway; negative regulation of ubiquitin-protein ligase activity; positive regulation of cell-cell adhesion; artery morphogenesis; ventricular cardiac muscle morphogenesis; negative regulation of protein ubiquitination; gene expression; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transforming growth factor beta receptor signaling pathway; negative regulation of cell migration

Disease: Colorectal Cancer, Susceptibility To, 3